Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

3518 ARTÍCULOS , VIENDO DEL 3106 AL 3120

[Surrogate marker for ABeta42]

Okochi M, Tagami S, Yanagida K, Takeda M.

Nihon Shinkei Seishin Yakurigaku Zasshi. 2010 Aug;30(4):169-72.

Correlation between cognitive impairment and CSF biomarkers in amnesic MCI, non-amnesic MCI, and Alzheimer's disease

Haldenwanger A, Eling P, Kastrup A, Hildebrandt H.

J Alzheimers Dis. 2010;22(3):971-80. doi: 10.3233/JAD-2010-101203.

Plasma cystatin C and risk of developing Alzheimer's disease in subjects with mild cognitive impairment

Ghidoni R, Benussi L, Glionna M, Desenzani S, Albertini V, Levy E, Emanuele E, Binetti G.

J Alzheimers Dis. 2010;22(3):985-91. doi: 10.3233/JAD-2010-101095.

HPA axis dysregulation associated to apolipoprotein E4 genotype in Alzheimer's disease

Gil-Bea FJ, Aisa B, Solomon A, Solas M, del Carmen Mugueta M, Winblad B, Kivipelto M, Cedazo-Mínguez A, Ramírez MJ.

J Alzheimers Dis. 2010;22(3):829-38. doi: 10.3233/JAD-2010-100663.

CSF levels of the histamine metabolite tele-methylhistamine are only slightly decreased in Alzheimer's disease

Motawaj M, Peoc'h K, Callebert J, Arrang JM.

J Alzheimers Dis. 2010;22(3):861-71. doi: 10.3233/JAD-2010-100381.

A comparison of the diagnostic sensitivity of MRI, CBF-SPECT, FDG-PET and cerebrospinal fluid biomarkers for detecting Alzheimer's disease in a memory clinic

Morinaga A, Ono K, Ikeda T, Ikeda Y, Shima K, Noguchi-Shinohara M, Samuraki M, Yanase D, Yoshita M, Iwasa K, Mastunari I, Yamada M.

Dement Geriatr Cogn Disord. 2010;30(4):285-92. doi: 10.1159/000320265. Epub 2010 Sep 22.

Atypical case of Alzheimer's disease mimicking Creutzfeldt-Jakob disease: interest of cerebrospinal fluid biomarkers in the differential diagnosis

Mahmoudi R, Manckoundia P, Morrone I, Lang PO, Dramé M, Novella JL.

J Am Geriatr Soc. 2010 Sep;58(9):1821-3. doi: 10.1111/j.1532-5415.2010.03051.x.

[Early diagnosis of Alzheimer's disease: the prodromal and preclinical phase]

Valls-Pedret C, Molinuevo JL, Rami L.

Rev Neurol. 2010 Oct 16;51(8):471-80.

Biomarkers for early detection of Alzheimer disease

Barber RC.

J Am Osteopath Assoc. 2010 Sep;110(9 Suppl 8):S10-5.

Cerebrospinal fluid biomarkers in Alzheimer's disease: are the hypotheses more dynamic than the biomarkers?

Spies PE, Verbeek MM, Olde Rikkert MG, Claassen JA.

J Am Geriatr Soc. 2010 Aug;58(8):1619-20. doi: 10.1111/j.1532-5415.2010.03001.x.

Alzheimer's disease genetics: current knowledge and future challenges

Hollingworth P, Harold D, Jones L, Owen MJ, Williams J.

Int J Geriatr Psychiatry. 2011 Aug;26(8):793-802. doi: 10.1002/gps.2628. Epub 2010 Oct 19.

Elevated 4-hydroxyhexenal in Alzheimer's disease (AD) progression

Bradley MA, Xiong-Fister S, Markesbery WR, Lovell MA.

Neurobiol Aging. 2012 Jun;33(6):1034-44. doi: 10.1016/j.neurobiolaging.2010.08.016. Epub 2010 Oct 20.

Identifying and validating biomarkers for Alzheimer's disease

Humpel C.

Trends Biotechnol. 2011 Jan;29(1):26-32. doi: 10.1016/j.tibtech.2010.09.007. Epub 2010 Oct 23.

Neurophysiology of Alzheimer's disease: towards understanding the relationship between the EEG phenotype and onset of Alzheimer's disease

Alves TC.

J Neurol Neurosurg Psychiatry. 2011 Jan;82(1):2. doi: 10.1136/jnnp.2010.224030. Epub 2010 Oct 25.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias